

Bypassing stereoselectivity in the early steps of alkaloid biosynthesis†

Peter Bernhardt,‡ Nancy Yerkes‡ and Sarah E. O'Connor*

Received 4th August 2009, Accepted 6th August 2009


First published as an Advance Article on the web 13th August 2009

DOI: 10.1039/b916027m

Total synthesis of glycosylated seco-iridoid stereoisomers allows the identification and bypassing of the stereoselectivity of early steps in monoterpene indole alkaloid biosynthesis.

Stereochemistry often determines how a natural product interacts with biological systems. For example, different stereoisomers can have different pharmacological profiles.¹ The biosynthetic enzymes that form natural products typically allow the production of only one stereoisomer, so fermentation of products with alternate stereochemistry must therefore bypass the stereochemical restrictions of biosynthetic pathway enzymes. Using synthetic seco-iridoid and strictosidine starting materials we show that the heteroyohimbine branch of monoterpene indole alkaloid (MIA) biosynthesis in the medicinal plant *Catharanthus roseus*^{2,3} has a surprisingly broad tolerance for stereochemical perturbations *in vitro*.

Strictosidine synthase catalyzes the first step in monoterpene indole alkaloid biosynthesis: an asymmetric Pictet–Spengler reaction between tryptamine **1** and secologanin **2** to yield strictosidine **3a** (Scheme 1).^{4,5} In the second step of this alkaloid pathway, **3a** is deglycosylated by strictosidine- β -D-glucosidase.^{6,7} This results in the formation of a hemiacetal that rearranges into a mixture of products that is channeled into one of several pathway branches. The enzymes responsible for these branching reactions are unknown at the genetic and biochemical levels. However, entry into the heteroyohimbine class of alkaloids (**5a–c**) is likely controlled by one or several NADPH-dependent reductases (Scheme 1).^{8,9}



Scheme 1 Heteroyohimbine biosynthesis. STS (strictosidine synthase) and SGD (strictosidine glucosidase) catalyze reactions that lead to a hemiacetal, which rearranges into a mixture of isomers; catenamine **4** is shown. Reduction leads to heteroyohimbines **5a–c**.

MIT Department of Chemistry, 77 Massachusetts Avenue, 18-592, Cambridge, MA 02139, USA. E-mail: soc@mit.edu; Fax: +1 617 324 0505; Tel: +1 617 324 0180

† Electronic supplementary information (ESI) available: Chemical synthesis, supplementary figures, methods. See DOI: 10.1039/b916027m

‡ These authors contributed equally to this work

Different heteroyohimbine alkaloid stereoisomers have different pharmacological activities. The heteroyohimbine alkaloid ajmalicine (raubasine) **5a** acts as a smooth muscle relaxant and as an α 1 anti-adrenergic,^{10–12} while tetrahydroalstonine **5b** acts as an α 2 anti-adrenergic.¹²

The stereogenic centers of strictosidine **3a**, the central intermediate for all monoterpene indole alkaloids, are either derived from the densely functionalized secologanin dihydropyran (C-15, C-20, and C-21) or the prochiral aldehyde carbon that is converted to the C-3 stereogenic center in strictosidine (Scheme 1). We recently reported that strictosidine glucosidase promotes not only deglycosylation of strictosidine **3a**, but also deglycosylation of vincoside **3b** (the 3-(R) diastereomer of **3a**).¹³ We report here that strictosidine glucosidase has an 80-fold higher specificity constant ($k_{\text{cat}}/K_{\text{M}}$) for **3a** compared to **3b** (Table 1). The kinetics show that the change in $k_{\text{cat}}/K_{\text{M}}$ is due to a change in turnover number (k_{cat}) while the Michaelis constant (K_{M}) remains the same for the two diastereomers (Table 1). In the crystal structure of SGD from the closely related *Rauvolfia serpentina* homolog (PDB: 2FJ6),¹⁴ the C-3 carbon atom of strictosidine **3a** is located near the surface of the protein. We speculate that the orientation of the glucose moiety, which is in the interior of the glucosidase, remains unchanged during turnover of vincoside **3b**, while the binding pocket for the more distal regions of the substrate, including the C-3 carbon, can accommodate **3b**.


We asked whether strictosidine glucosidase can catalyze the conversion of alternate dihydropyran stereoisomers of **3a**, derived from the C-2 and C-4 positions of secologanin **2**. This has not been tested previously, as alternate stereoisomers of **2** are not readily available. To access alternate configurations, we applied and expanded the previously reported synthesis of acetal-protected 9,10-nor-secologanin aglycones.^{15,16} The key step is Tietze's tandem Knoevenagel–hetero-Diels–Alder (KHDA) reaction, which assembles the dihydropyran from **7**, **8**, and an electron rich dienophile (e.g. vinyl ether). We adopted this strategy to, for the first time, obtain *O*-glucosylated 9,10-nor-strictosidine **12a** and its stereoisomers **12** (Scheme 2). The KHDA substrate, 2,3,4,6-tetrabenzyl vinyl-glucose **6**, was synthesized by Ir-catalyzed vinyl transfer from vinyl acetate to the corresponding alcohol.¹⁷ After the KHDA reaction of **6**, **7**, and **8**, in the presence of potassium fluoride, the cycloadduct was subjected to methanolysis to generate methyl ester **9**. Pd-catalyzed debenzylation of **9** afforded acetal-protected secologanin **10** as a mixture of inseparable stereoisomers. After acetal hydrolysis, 9,10-nor-secologanin **11** was carried into either an enzymatic or a non-enzymatic Pictet–Spengler reaction to generate the corresponding tetrahydro- β -carboline products **12a** and **12** (Scheme 2).

Isomers **12** were synthesized in acidic buffer from **1** and **11** (Scheme 2), and purified by preparative HPLC. Each separable peak was characterized by ¹H NMR (ESI†). Analysis of the

Table 1 Steady-state kinetic constants

Strictosidine glucosidase kinetics ^a	k_{cat} [s ⁻¹]	K_M [mM]	k_{cat}/K_M [M ⁻¹ s ⁻¹]	Reductase kinetics ^b	V_{max} [U mg ⁻¹] ^b	K_M [mM]	V_{max}/K_M [U M ⁻¹ mg ⁻¹] ^b
3a	15 ± 0.8	0.15 ± 0.03	$1.0 \times 10^2 \pm 0.2 \times 10^2$	Deglycosylated 3a	0.027 ± 0.001	0.10 ± 0.02	0.26 ± 0.04
3b	0.19 ± 0.01	0.15 ± 0.04	1.3 ± 0.3	Deglycosylated 3b	0.012 ± 0.0003	0.66 ± 0.04	$1.9 \times 10^{-2} \pm 0.1 \times 10^{-2}$

^a Activity quantified by monitoring the disappearance of starting material at pH 6.0, 30 °C. ^b 1 U = 1 μmol product formed per minute at pH 7.0, 30 °C. Apparent kinetic constants obtained from partially purified enzyme.



Scheme 2 Synthesis of **12** and **12a**, **13a**, and **13**. a) K_F, toluene; b) DBU, CH₃OH, 38% over 2 steps; c) Pd/C, CH₃OH, 77%; d) PPTS (2 eq., 0.2 M), acetone/H₂O (2:1), ~10%; e) **1**, *C. roseus* STS, NaP_i (0.05 M, pH 7.0), 89%; f) **1**, maleic acid buffer (0.01 M, pH 2.0); g) *C. roseus* SGD, citrate-phosphate buffer (0.15 M, pH 6.0); h) *B. stearothermophilus* α-glucosidase, almond β-glucosidase, strictosidine glucosidase, citrate phosphate buffer (0.15 M, pH 6.0); (i) reductase activity from *C. roseus* cell suspension culture, NADPH, NaP_i (0.05 M, pH 7.0).

mixture by UPLC-MS resolved six peaks, each with a mass consistent with 18,19-nor-strictosidine **12** ($m/z = 505$ [M + H]⁺) (Fig. 1A (i): pk 1–6). In contrast, the strictosidine synthase-catalyzed reaction between **1** and **11** resulted in the appearance of a single product, **12a**, which was isolated and characterized by NMR (ESI⁺). The doublet of a doublet at 5.8 ppm suggested a dihydropyran 2,4-*trans* configuration (Scheme 1),^{15,16} and the doublet at 4.8 ppm with a *J*-coupling constant of 7.8 Hz suggested a β-anomeric configuration for the glycoside linkage.¹⁸ Compound **12a** therefore contains the same relative stereochemistry found in natural strictosidine. Compound **12a** co-eluted with the third peak observed in the LC chromatogram of **12**, indicating the presence and location of the natural stereoisomer among the mixture of the chemical reaction products. Therefore, strictosidine synthase, when challenged with an array of stereoisomers, displays a stringent preference for the diastereomer displaying the 2,4-*trans* configuration and β-glycoside bond found in the natural substrate. As an alternative to enzymatic synthesis, chemical synthesis of **12** from **1** and **11** allowed us to bypass the stringent selectivity of strictosidine synthase and assess stereochemical restrictions of subsequent biosynthetic steps. Analysis of the reaction of unnatural strictosidine stereoisomers with downstream enzymes therefore utilized chemically synthesized **12**.




Fig. 1 A Remaining starting material after deglycosylation of **12** (m/z 505.1 ± 0.5) by *C. roseus* strictosidine glucosidase (ii), almond β-glucosidase (β, iii), and *B. stearothermophilus* α-glucosidase (α, iv) monitored by UPLC-MS, (i) no-enzyme control; B. Reductase assay. (i) reduction of **12** yields two separable stereoisomers **13**; (ii) reduction of deglycosylated **12a** yields a single product **13a**; (iii) reduction of deglycosylated d₄-strictosidine **3a** (m/z 357); (iv) reduction of deglycosylated d₄-vincoside **3b** (m/z 357); (v) ajmalicine **5a** standard (m/z 353).

Strictosidine glucosidase could efficiently deglycosylate tetrahydro-β-carboline **12a**, the isomer with the natural 2,4-*trans* configuration. When strictosidine glucosidase was incubated with all isomers of **12**, only two of the six separable peaks decreased in area (Fig. 1A (ii): pk 1 and pk 3). One peak (pk 3) co-eluted with **12a** (not shown), suggesting that the compound with natural *trans* stereochemistry is turned over. Pk 1 was isolated by preparative HPLC and subjected to NMR spectroscopy. The ¹H NMR spectrum showed the presence of two stereoisomers, both with H15/H21-*cis* configuration, as evidenced by the triplets at 5.9 and 5.7 ppm, assigned to H-21 (ESI⁺).^{15,16} The anomeric configuration of the glucose moiety is likely β as indicated by the *J*-coupling constant of 8.0 Hz.¹⁸ We conclude that strictosidine glucosidase accommodates stereochemical perturbation in the secologanin dihydropyran moiety, but the anomeric configuration must be β for turnover to occur.

To fully explore the stereochemical promiscuity of the subsequent reductase catalyzed step, complete deglycosylation of **12** is

required. However, strictosidine glucosidase only deglycosylated a few of the stereoisomers of **12**. Since it has been previously shown that strictosidine **3a** can be deglycosylated by bacterial glycosidases,¹⁹ we examined whether two commercially available glucosyl hydrolases, *Bacillus stearothermophilus* α -glucosidase and almond β -glucosidase, display different deglycosylation patterns compared to strictosidine glucosidase. Almond β -glucosidase was considerably more permissive than strictosidine glucosidase, consuming four out of the six peaks in the chromatogram (Fig. 1A (iii): pk 1, 3, 5, and 6), *B. stearothermophilus* α -glucosidase facilitated the consumption of two peaks that were not converted by either β -glucosidase (Fig. 1A (iv): pk 2 and 4). Strictosidine glucosidase therefore appears to be more specific for its substrate, **12a**, while the two commercially available glucosidases likely have active sites that allow a greater diversity of substrates to be accepted. By using glucosidases from different metabolic pathways, it is possible to bypass the native biosynthetic pathway to fully deglycosylate **12**.

In the heteroyohimbine biosynthetic pathway, one or more reductases catalyze the NADPH-dependent reduction of deglycosylated strictosidine **3a** to form monoterpene indole alkaloids such as **5a–c** (Scheme 1). A cell-free extract from *C. roseus* cell suspension culture was used to reconstitute the reductase activity. Control experiments revealed that **3a**, strictosidine glucosidase, NADPH, and the reductase activity were each a necessary component for formation of a reduced product that eluted near an authentic standard of ajmalicine **5a** (Fig. 1B). We determined the steady-state kinetics for reduction of the natural substrate, deglycosylated strictosidine **3a**, and the unnatural substrate, deglycosylated vincoside **3b** (Table 1). The enzyme showed a 15-fold catalytic preference (V_{\max}/K_M) for the 3-(*S*) stereochemistry of strictosidine **3a** ($0.26 \text{ U M}^{-1} \text{ mg}^{-1}$) over the 3-(*R*) stereochemistry of vincoside **3b** ($0.019 \text{ U M}^{-1} \text{ mg}^{-1}$). This was mainly due to a 7-fold difference in K_M (0.1 mM compared to 0.7 mM with **3a** and **3b**, respectively). The catalytic differentiation between **3a** and **3b** suggests that the reductase activity derives from the monoterpene indole alkaloid pathway. However, since the enzyme was not purified to homogeneity, despite extensive efforts, we cannot rigorously exclude the involvement of additional reductases in the turnover of deglycosylated **3a** or **3b**.

Deglycosylated 18,19-nor-strictosidine **12a** was converted by the reductase into a compound with a ¹H NMR spectrum and mass consistent with **13a** (Scheme 2, and ESI[†]). When reductase activity and NADPH was added to deglycosylated **12**, which contained all stereoisomers, two separable reduced products formed; one product coeluted with **13a** (Fig. 1B). The reduced product contains two stereogenic centers, C-3 and C-15 (Scheme 2), and only two sets of enantiomers are expected to separate under the chromatographic conditions. Since **12** was completely deglycosylated, and because all deglycosylated **12** was completely consumed upon addition of the reductase activity (ESI[†]), we conclude that the reductase turns over all secologanin dihydropyran configurations. The reductase(s) that generate heteroyohimbine alkaloids appear to be capable of acting upon a wide variety of substrates. This suggests that

this reductase(s) will have broad applications in chemoenzymatic synthesis after efforts to clone the enzyme are successful. Synthetic installation of the vinyl group on **11** will allow access to an even broader range of alkaloid structures.

The first step of the pathway, catalyzed by strictosidine synthase, may have evolved stringent substrate specificity to ensure the integrity of the first committed intermediate strictosidine **3a**. Strictosidine glucosidase also shows strict stereocontrol, but accepts at least one unnatural dihydropyran stereoisomer with relative *cis* stereochemistry. Recruitment of glucosidases from other metabolic pathways highlights the potential to bypass stereochemical restrictions and to diversify alkaloid biosynthesis. Assay of **3a**, **3b**, **12a**, and **12** with heteroyohimbine reductase activity suggests that *C. roseus* harbors at least one enzyme that converts these stereoisomers to reduced alkaloids *in vitro*. Regardless of whether the observed activity is functional *in vivo*, this enzyme can be used in heterologous expression systems to yield novel variants of the heteroyohimbine framework. This approach requires the gene encoding this enzyme, and efforts to identify the NADPH dependent reductases of *C. roseus* are ongoing.

Acknowledgements

We gratefully acknowledge funding from GM074820.

Notes and references

- 1 W. H. De Camp, *Chirality*, 1989, **1**, 2–6.
- 2 R. Van der Heijden, D. I. Jacobs, W. Snoeijer and D. V. Hallard, R., *Curr. Med. Chem.*, 2004, **11**, 607–628.
- 3 S. E. O'Connor and J. Maresh, *Nat. Prod. Rep.*, 2006, **23**, 532–547.
- 4 X. Ma, S. Panjikar, J. Koepke, E. Loris and J. Stöckigt, *Plant Cell*, 2006, **18**, 907–920.
- 5 J. J. Maresh, L. A. Giddings, A. Friedrich, E. A. Loris, S. Panjikar, B. L. Trout, J. Stöckigt, B. Peters and S. E. O'Connor, *J. Am. Chem. Soc.*, 2008, **130**, 710–723.
- 6 I. Gerasimenko, Y. Sheludko, X. Ma and J. Stöckigt, *Eur. J. Biochem.*, 2002, **269**, 2204–2213.
- 7 A. Geerlings, M. M.-L. Ibanez, J. Memelink, R. Van der Heijden and R. Verpoorte, *J. Biol. Chem.*, 2000, **275**, 3051–3056.
- 8 T. Hemscheidt and M. H. Zenk, *Plant Cell Rep.*, 1985, **4**, 216–219.
- 9 J. Stöckigt, T. Hemscheidt, G. Hofle, P. Heinsteinst and V. Formacek, *Biochemistry*, 1983, **22**, 3448–3452.
- 10 G. Brevetti, M. Chiariello, S. Verrienti, M. Spina, M. Desiderati and M. Condorelli, *Angiology*, 1983, **34**, 517–526.
- 11 S. Li, J. Long, Z. Ma, Z. Xu, J. Li and Z. Zhang, *Curr. Med. Res. Opin.*, 2004, **20**, 409–415.
- 12 J. Roquebert and P. Demichel, *Eur. J. Pharmacol.*, 1984, **106**, 203–205.
- 13 N. Yerkes, J. X. Wu, E. McCoy, M. C. Galan, S. Chen and S. E. O'Connor, *Bioorg. Med. Chem. Lett.*, 2008, **18**, 3095–3098.
- 14 L. Barleben, S. Panjikar, M. Ruppert, J. Koepke and J. Stöckigt, *Plant Cell*, 2007, **19**, 2886–2897.
- 15 L. F. Tietze, H. Meier and H. Nutt, *Liebigs Ann. Chem.*, 1990, 253–260.
- 16 L. F. Tietze, *Angew. Chem.*, 1983, **95**, 840–853.
- 17 Y. Okimoto, S. Sakaguchi and Y. Ishii, *J. Am. Chem. Soc.*, 2002, **124**, 1590–1591.
- 18 M. L. Sinnott, *Carbohydrate Chemistry and Biochemistry: Structure and Mechanism*, Royal Society of Chemistry, 2007.
- 19 S. Zhengwu, W. Eisenreich and T. M. Kutchan, *Phytochemistry*, 1998, **48**, 293–296.